Therapeutic Inertia With Initial Low-Dose Quadruple Combination Therapy for Hypertension: Results From the QUARTET Trial.

blood pressure cardiovascular diseases heart rate hypertension risk factors therapeutic inertia

Journal

Hypertension (Dallas, Tex. : 1979)
ISSN: 1524-4563
Titre abrégé: Hypertension
Pays: United States
ID NLM: 7906255

Informations de publication

Date de publication:
13 Mar 2024
Historique:
medline: 13 3 2024
pubmed: 13 3 2024
entrez: 13 3 2024
Statut: aheadofprint

Résumé

Low-dose combinations are a promising intervention for improving blood pressure (BP) control but their effects on therapeutic inertia are uncertain. Analysis of 591 patients randomized to an ultra-low-dose quadruple pill or initial monotherapy. The episode of therapeutic inertia was defined as a patient visit with a BP of >140/90 mm Hg without intensification of antihypertensive treatment. We compared the frequency of therapeutic inertia episodes between Quadpill and initial monotherapy as a proportion of the total population (intention-to-treat analysis with the denominator being all participants randomized) and as a proportion of people with uncontrolled BP (with the denominator being participants with uncontrolled BP). Therapeutic inertia occurred in fewer participants randomized to Quadpill compared with monotherapy. For example, among the 390 participants with a 6-month follow-up, therapeutic inertia according to unattended BP was 21/192 (11%) versus 45/192 (23%), Among all treated individuals, low-dose Quadpill reduced the number of therapeutic inertia episodes compared with initial monotherapy. After the first follow-up visit, most high BP values did not lead to treatment intensification in both groups. Education is needed about the importance of treatment intensification despite a significant improvement in BP or BP being close to target. URL: XXX; Unique identifier: ACTRN12616001144404.

Sections du résumé

BACKGROUND UNASSIGNED
Low-dose combinations are a promising intervention for improving blood pressure (BP) control but their effects on therapeutic inertia are uncertain.
METHODS UNASSIGNED
Analysis of 591 patients randomized to an ultra-low-dose quadruple pill or initial monotherapy. The episode of therapeutic inertia was defined as a patient visit with a BP of >140/90 mm Hg without intensification of antihypertensive treatment. We compared the frequency of therapeutic inertia episodes between Quadpill and initial monotherapy as a proportion of the total population (intention-to-treat analysis with the denominator being all participants randomized) and as a proportion of people with uncontrolled BP (with the denominator being participants with uncontrolled BP).
RESULTS UNASSIGNED
Therapeutic inertia occurred in fewer participants randomized to Quadpill compared with monotherapy. For example, among the 390 participants with a 6-month follow-up, therapeutic inertia according to unattended BP was 21/192 (11%) versus 45/192 (23%),
CONCLUSIONS UNASSIGNED
Among all treated individuals, low-dose Quadpill reduced the number of therapeutic inertia episodes compared with initial monotherapy. After the first follow-up visit, most high BP values did not lead to treatment intensification in both groups. Education is needed about the importance of treatment intensification despite a significant improvement in BP or BP being close to target.
REGISTRATION UNASSIGNED
URL: XXX; Unique identifier: ACTRN12616001144404.

Identifiants

pubmed: 38477128
doi: 10.1161/HYPERTENSIONAHA.123.22284
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Nelson Wang (N)

The George Institute for Global Health, UNSW Sydney (N.W., A.R., T.U., J.C., E.R.A., L.B.).

Amy von Huben (A)

MBiostats, Faculty of Medicine and Health, Menzies Centre for Health Policy and Economics, The University of Sydney, Australia. (A.v.H.).

Simone Marschner (S)

Faculty of Medicine and Health, Westmead Applied Research Centre, The University of Sydney, Australia. (S.M., T.U., C.R., C.C.).

Mark Nelson (M)

Menzies Institute for Medical Research, University of Tasmania (M.N.).

Janis M Nolde (JM)

Dobney Hypertension Centre, Medical School Royal Perth Hospital Unit, The University of Western Australia (J.M.N., M.S.).

Markus Schlaich (M)

Dobney Hypertension Centre, Medical School Royal Perth Hospital Unit, The University of Western Australia (J.M.N., M.S.).

Gemma Figtree (G)

Kolling Institute of Medical Research, Royal North Shore Hospital,The University of Sydney, Australia. (G.F.).

Graham Hillis (G)

Department of Cardiology, Royal Perth Hospital (G.H.).

Tim Usherwood (T)

The George Institute for Global Health, UNSW Sydney (N.W., A.R., T.U., J.C., E.R.A., L.B.).
Faculty of Medicine and Health, Westmead Applied Research Centre, The University of Sydney, Australia. (S.M., T.U., C.R., C.C.).

Christopher Reid (C)

Faculty of Medicine and Health, Westmead Applied Research Centre, The University of Sydney, Australia. (S.M., T.U., C.R., C.C.).
Research & Data Analytics Hub, School of Population Health, Curtin University (C.R.).

John Chalmers (J)

The George Institute for Global Health, UNSW Sydney (N.W., A.R., T.U., J.C., E.R.A., L.B.).

Shirley Jansen (S)

Curtin Medical School, Curtin University, Perth, WA (S.J.).

Emily R Atkins (ER)

The George Institute for Global Health, UNSW Sydney (N.W., A.R., T.U., J.C., E.R.A., L.B.).

Laurent Billot (L)

The George Institute for Global Health, UNSW Sydney (N.W., A.R., T.U., J.C., E.R.A., L.B.).

Clara Chow (C)

Faculty of Medicine and Health, Westmead Applied Research Centre, The University of Sydney, Australia. (S.M., T.U., C.R., C.C.).

Anthony Rodgers (A)

The George Institute for Global Health, UNSW Sydney (N.W., A.R., T.U., J.C., E.R.A., L.B.).

Classifications MeSH